Understanding Payer Evidentiary Needs for Alzheimer’s Disease Monoclonal Antibody Treatments

Event

FDA Convening

Understanding Payer Evidentiary Needs for Alzheimer’s Disease Monoclonal Antibody Treatments

Understanding Payer Evidentiary Needs for Alzheimer’s Disease Monoclonal Antibody Treatments
July 14, 2021
10:00 AM-3:45 PM


Roundtable Objective:
Important progress in clinical research and innovative Alzheimer’s Disease monoclonal antibody (AD mAb) drug development has been made over the last decade, and potentially transformative treatments may be on the horizon. However, the opportunity to treat patients with this new class of therapies will be accompanied by questions related to patient access, treatment costs, and long-term data collection on patient outcomes.


This multistakeholder roundtable will explore the issues associated with the use of these AD mAb treatments that are important to the payer communities. Specifically, sessions will focus on the broader therapeutic class landscape, how payer groups envision continuing evidence development efforts in a postmarket setting, and ideas for working together to track utilization and patient outcomes. This roundtable will not focus on the approval process or approval requirements for any mAb therapy.